This approval marks NeuroStar as the first and only transcranial magnetic stimulation (TMS) therapy cleared by the FDA for use in this younger demographic, expanding its indications to a fourth ...

The transcranial magnetic stimulation (TMS) device is cleared for use as an adjunct treatment in patients aged 15-21 years ...

A real-world study revealed impressive results for NeuroStar TMS treatment. An 83% response rate was reported, meaning that the majority of patients who completed their treatment experienced ...

doi: 10.1136/bmjopen-2022-063095 4. FDA Clears NeuroStar TMS for Treatment of MDD in Adolescents Disclaimer: Dr. Brenner in is private practice in Manhattan, and has been a TMS clinician since ...

For more information about NeuroStar TMS Therapy, visit www.NeuroStar.com. About NeuroneticsNeuronetics, Inc. believes that mental health is as important as physical health. As a global leader in ...

Preliminary unaudited fourth quarter and full year revenue 2024 was $22.1 and $74.5, respectivelyClosed acquisition of Greenbrook TMS effective ...

In a report released yesterday, William Plovanic from Canaccord Genuity maintained a Buy rating on Neuronetics (STIM – Research Report), with a ...

NeuroStar Advanced TMS Therapy is designed specifically for the treatment of major depressive disorders within adult patients who have not satisfactorily improved from previous use of ...